Suffruticosol B from Paeonia lactiflora Ameliorates Alzheimer's Disease Pathology by Inhibiting MAO ‐B Activity

Fuente: Wiley Open Access
Saved in:
Bibliographic Details
Main Authors: Jae‐Jun Heo, Young‐Eun Han, Min Soo Kim, Eunji Cheong, Chun Whan Choi, Soo‐Jin Oh
Format: Artículo Open Access
Published: Wiley 2024
Subjects:
Online Access:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867017066393894912
author Jae‐Jun Heo
Young‐Eun Han
Min Soo Kim
Eunji Cheong
Chun Whan Choi
Soo‐Jin Oh
author_facet Jae‐Jun Heo
Young‐Eun Han
Min Soo Kim
Eunji Cheong
Chun Whan Choi
Soo‐Jin Oh
Jae‐Jun Heo
Young‐Eun Han
Min Soo Kim
Eunji Cheong
Chun Whan Choi
Soo‐Jin Oh
collection Wiley Open Access
contents Suffruticosol B from Paeonia lactiflora Ameliorates Alzheimer's Disease Pathology by Inhibiting MAO ‐B Activity Jae‐Jun Heo Young‐Eun Han Min Soo Kim Eunji Cheong Chun Whan Choi Soo‐Jin Oh Phytotherapy Research ABSTRACT Monoamine oxidase B (MAO‐B) has emerged as a therapeutic target for Alzheimer's disease (AD) due to its involvement in the synthesis of γ‐aminobutyric acid (GABA) in reactive astrocytes, which inhibits neuronal activity. Suffruticosol B (Suf‐B), isolated from Paeonia lactiflora , is one of the resveratrol oligomers. Although resveratrol oligomers have demonstrated neuroprotective effects, it remains unexplored whether Suf‐B exerts therapeutic effects on AD by targeting MAO‐B. In this study, we investigated whether Suf‐B alleviates AD pathology by mitigating reactive astrogliosis and inhibiting the overproduction of astrocytic GABA. After confirming the MAO‐B inhibitory effect of Suf‐B through MAO‐B enzyme assay, we administered Suf‐B to APP/PS1 AD model mice. To test the potential therapeutic action of Suf‐B in AD, a series of experiments were conducted, including behavioral tests such as the open field test, novel object recognition test, Barnes maze test, passive avoidance test, as well as immunohistochemistry and whole‐cell patch‐clamp recordings. We found that Suf‐B markedly inhibited MAO‐B activity without causing cytotoxicity. Immunohistochemistry and electrophysiology experiments demonstrated that Suf‐B significantly reduced astrocyte reactivity, as well as an aberrant increase in GABA production and tonic GABA release from astrocytes in AD. Behavior test results indicated that Suf‐B treatment restored cognitive function in APP/PS1 mice. In conclusion, Suf‐B effectively reduces excessive GABA production in reactive astrocytes by inhibiting MAO‐B, normalizing aberrant inhibition in hippocampal neurons in an AD mouse model. These results suggest that Suf‐B has potential as a treatment for AD and may be applicable to other brain diseases associated with reactive astrogliosis. 10.1002/ptr.8395 http://creativecommons.org/licenses/by/4.0/
doi_str_mv 10.1002/ptr.8395
format Artículo Open Access
id wiley_oa_10_1002_ptr_8395
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by/4.0/
publishDate 2024
publisher Wiley
record_format wiley_oa
spellingShingle Suffruticosol B from Paeonia lactiflora Ameliorates Alzheimer's Disease Pathology by Inhibiting MAO ‐B Activity
Jae‐Jun Heo
Young‐Eun Han
Min Soo Kim
Eunji Cheong
Chun Whan Choi
Soo‐Jin Oh
Phytotherapy Research
Suffruticosol B from Paeonia lactiflora Ameliorates Alzheimer's Disease Pathology by Inhibiting MAO ‐B Activity Jae‐Jun Heo Young‐Eun Han Min Soo Kim Eunji Cheong Chun Whan Choi Soo‐Jin Oh Phytotherapy Research ABSTRACT Monoamine oxidase B (MAO‐B) has emerged as a therapeutic target for Alzheimer's disease (AD) due to its involvement in the synthesis of γ‐aminobutyric acid (GABA) in reactive astrocytes, which inhibits neuronal activity. Suffruticosol B (Suf‐B), isolated from Paeonia lactiflora , is one of the resveratrol oligomers. Although resveratrol oligomers have demonstrated neuroprotective effects, it remains unexplored whether Suf‐B exerts therapeutic effects on AD by targeting MAO‐B. In this study, we investigated whether Suf‐B alleviates AD pathology by mitigating reactive astrogliosis and inhibiting the overproduction of astrocytic GABA. After confirming the MAO‐B inhibitory effect of Suf‐B through MAO‐B enzyme assay, we administered Suf‐B to APP/PS1 AD model mice. To test the potential therapeutic action of Suf‐B in AD, a series of experiments were conducted, including behavioral tests such as the open field test, novel object recognition test, Barnes maze test, passive avoidance test, as well as immunohistochemistry and whole‐cell patch‐clamp recordings. We found that Suf‐B markedly inhibited MAO‐B activity without causing cytotoxicity. Immunohistochemistry and electrophysiology experiments demonstrated that Suf‐B significantly reduced astrocyte reactivity, as well as an aberrant increase in GABA production and tonic GABA release from astrocytes in AD. Behavior test results indicated that Suf‐B treatment restored cognitive function in APP/PS1 mice. In conclusion, Suf‐B effectively reduces excessive GABA production in reactive astrocytes by inhibiting MAO‐B, normalizing aberrant inhibition in hippocampal neurons in an AD mouse model. These results suggest that Suf‐B has potential as a treatment for AD and may be applicable to other brain diseases associated with reactive astrogliosis. 10.1002/ptr.8395 http://creativecommons.org/licenses/by/4.0/
title Suffruticosol B from Paeonia lactiflora Ameliorates Alzheimer's Disease Pathology by Inhibiting MAO ‐B Activity
topic Phytotherapy Research
url https://onlinelibrary.wiley.com/doi/10.1002/ptr.8395